GBA-Associated Parkinson's Disease and Other Synucleinopathies

Curr Neurol Neurosci Rep. 2018 Jun 8;18(8):44. doi: 10.1007/s11910-018-0860-4.


Purpose of review: GBA mutations are the most common known genetic cause of Parkinson's disease (PD). Its biological pathway may be important in idiopathic PD, since activity of the enzyme encoded by GBA, glucocerebrosidase, is reduced even among PD patients without GBA mutations. This article describes the structure and function of GBA, reviews recent literature on the clinical phenotype of GBA PD, and suggests future directions for research, counseling, and treatment.

Recent findings: Several longitudinal studies have shown that GBA PD has faster motor and cognitive progression than idiopathic PD and that this effect is dose dependent. New evidence suggests that GBA mutations may be important in multiple system atrophy. Further, new interventional studies focusing on GBA PD are described. These studies may increase the interest of PD patients and caregivers in genetic counseling. GBA mutation status may help clinicians estimate PD progression, though mechanisms underlying GBA and synucleinopathy require further understanding.

Keywords: Genetics; Glucocerebrosidase; Parkinson’s disease; Synucleinopathy.

Publication types

  • Review

MeSH terms

  • Female
  • Glucosylceramidase / genetics*
  • Humans
  • Male
  • Middle Aged
  • Multiple System Atrophy / diagnosis
  • Multiple System Atrophy / genetics
  • Multiple System Atrophy / physiopathology
  • Mutation / genetics
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / genetics*
  • Parkinson Disease / physiopathology
  • Phenotype
  • Synucleins / genetics*


  • Synucleins
  • GBA protein, human
  • Glucosylceramidase